Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma
Authors:
- 1 January 2005
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 46 (3) , 477-479
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Adhesion of 8226 Myeloma Cell Lines Induces over Expression of HSP70 and its Inhibition Reverses CAM-DR and Acquired Drug Resistance in Multiple Myeloma.Blood, 2004
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based studyAnnals of Hematology, 2001
- The national institute on aging and the national cancer institute seer collaborative study on comorbidity and early diagnosis of cancer in the elderlyCancer, 1994
- The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1988